Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | TK2 | O00142 | 4/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19504244 | 0.84 | KIF11 (0.43) | KIF11ALDH1A1TSHRPTPN1ALOX15 | |
| SCHEMBL19469823 | 0.79 | KIF11 (0.46) | KIF11ALDH1A1TSHRPTPN1ALOX15 | |
| SCHEMBL5872334 | 0.78 | KIF11 (0.52) | KIF11ALDH1A1TSHRPTPN1TACR1 | |
| SCHEMBL14359797 | 0.74 | ALDH1A1 (0.44) | KIF11ALDH1A1TSHRPTPN1ALOX15 | |
| SCHEMBL8850056 | 0.74 | KIF11 (0.52) | KIF11ALDH1A1ALOX15MAPK1HRH4 | |
| SCHEMBL19504433 | 0.73 | KIF11 (0.43) | KIF11ALDH1A1TSHRPTPN1ALOX15 | |
| SCHEMBL19474691 | 0.73 | KIF11 (0.43) | KIF11ALDH1A1TSHRPTPN1ALOX15 | |
| SCHEMBL17297687 | 0.72 | KIF11 (0.61) | KIF11TSHRMAPK1HRH4TK2 | |
| SCHEMBL21068605 | 0.72 | KIF11 (0.39) | KIF11TSHRPTPN1TACR1HRH4 | |
| SCHEMBL8571973 | 0.71 | KIF11 (0.54) | KIF11ALDH1A1TSHRPTPN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383895-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| US-12077530-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2024-09-03 | — | — | US | disclosed |
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2021-09-16 | — | — | US | disclosed |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2021-09-16 | — | — | US | disclosed |
| US-10961241-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-10961241-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-20200239467-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| US-20200239467-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
| WO-2017182493-A1 | INDAZOLE DERIVATIVES FOR USE IN DOWN-REGULATION OF THE ESTROGEN RECEPTOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |
| US-20170305909-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305909-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| WO-2017182493-A1 | INDAZOLE DERIVATIVES FOR USE IN DOWN-REGULATION OF THE ESTROGEN RECEPTOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-10-26 | — | — | WO | disclosed |
| US-20170305909-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239467-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KIF11 1807/4885ALDH1A1 50/4885TSHR 3246/4885 |
| US-20170305909-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KIF11 2088/4885ALDH1A1 35/4885TSHR 3354/4885 |
| US-10961241-B2 | Chemical compounds | MKI67, CCNI, MCL1 | KIF11 1807/4885ALDH1A1 50/4885TSHR 3246/4885 |
| US-12077530-B2 | Chemical compounds | MKI67, CCNI, MCL1 | KIF11 1807/4885ALDH1A1 50/4885TSHR 3246/4885 |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KIF11 1807/4885ALDH1A1 50/4885TSHR 3246/4885 |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KIF11 1807/4885ALDH1A1 50/4885TSHR 3246/4885 |
| US-20240383895-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KIF11 1807/4885ALDH1A1 50/4885TSHR 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.